Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy

Status Active, not recruiting

Clinical Trial Summary

Peanut allergy is the most common cause of severe allergic reactions to food. Onset is common in childhood, but in contrast to other food allergies such as cow's milk and egg, peanut allergy tends to persist into adulthood. It is associated with a significant impact on quality of life, both for the affected individual and their family. There is no current cure for peanut allergy. Oral peanut immunotherapy (OIT) using defatted, roasted peanut flour has been demonstrated to offer potential in this regard, but is associated with significant and frequent reactions and can cause life-threatening allergic symptoms. The investigators have previously demonstrated that the processing of peanuts through boiling results in a relatively hypoallergenic product due to the loss of key allergenic components from peanut into the water. This has been tested in a recently-completed Phase 2b/3 trial (The BOPI Study, Clinicaltrials.gov NCT02149719; HRA reference 15/LO/0287): 47 children/ young people with peanut allergy confirmed at double-blind, placebo-controlled food challenge (DBPCFC) were randomised (2:1) to receive either oral immunotherapy (updosing using boiled peanut for ~6 months, followed by maintenance with roasted peanut) or standard treatment (allergen avoidance). Participants underwent repeat DBPCFC at 12 months to assess response, following which peanut OIT was stopped and sustained unresponsiveness assessed after 4 weeks (4SU). 24/32 participants (100% per protocol) achieved the primary outcome of desensitisation to >1.44g peanut protein (approximately 6-8 peanuts, p<0.0001); of those 14 tolerated >4.4g peanut protein. 13/24 participants achieved 4SU. There was no significant change in threshold in the control group (p>0.05). Boiled peanut OIT had a favourable safety profile, with under 2% of doses associated with gastrointestinal symptoms. The BOPI-2 study is a non-inferiority study to demonstrate that boiled peanut is at least as effective as peanut flour in treating children with peanut allergy. The study will compare the rate of adverse events and other safety outcomes between these two interventions, and assess the immunological mechanisms involved, a secondary aim being to develop clinically-useful predictors for identifying individuals likely to undergo successful desensitisation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03937726
Study type	Interventional
Source	Imperial College London
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 29, 2019
Completion date	May 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01904604` - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial	Phase 2
Recruiting	`NCT00243555` - Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut	N/A
Recruiting	`NCT01429896` - The Effect of Extrinsic Factors on Food Allergy	Phase 2
Completed	`NCT00850668` - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults	Phase 1
Active, not recruiting	`NCT04090203` - Boiled Peanut Oral Immunotherapy	Phase 1
Completed	`NCT00382148` - A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g	Phase 2
Completed	`NCT01084174` - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy	Phase 1/Phase 2
Recruiting	`NCT05695261` - Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients	Phase 2
Completed	`NCT01373242` - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance	Phase 1/Phase 2
Completed	`NCT02424136` - PEAnut Anaphylaxis Predictors	N/A
Completed	`NCT00932282` - Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy	Phase 1/Phase 2
Completed	`NCT00356174` - An Observational Study of Childhood Food Allergy	N/A
Completed	`NCT02304991` - FARE Peanut SLIT and Early Tolerance Induction	Phase 2
Recruiting	`NCT05621317` - A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy	Phase 2
Recruiting	`NCT03679676` - Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)	Phase 2
Completed	`NCT00580606` - A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial	Phase 1/Phase 2
Completed	`NCT02665793` - Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study	N/A
Completed	`NCT01867671` - Peanut Oral Immunotherapy in Children	Phase 2
Completed	`NCT00815035` - Oral Immunotherapy (OIT) for Peanut Allergy	Phase 2
Completed	`NCT01891136` - Oral Peanut Immunotherapy for Peanut Allergic Patients	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy — BOPI-2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms